New First-Line Option for Highly Mutated CRC?

A new study shows that the dual immunotherapy combination of nivolumab (Opdivo, Bristol Myers Squibb [BMS]) plus ipilimumab (Yervoy, BMS) reduced the risk for disease progression or death by 79% (hazard ratio, 0.21; 95% CI, 0.14-0.32; P<0.0001) compared with chemotherapy with or without targeted therapies, as first-line treatment in patients with microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). The research was presented